Skip to main content

Table 1 Pharmacological characterization of PPAR induction of zebrafish fabp1a and fabp1b.1 promoter activity

From: Subfunctionalization of peroxisome proliferator response elements accounts for retention of duplicated fabp1 genes in zebrafish

fabp1a

 

WY14643

Rosiglitazone

 

-

GW6471

T0070907

Δ5’FR

ΔDR1

-

GW6471

T0070907

Δ5’FR

ΔDR1

E max (RLU)

152.80 ± 3.44

152.00 ± 7.80

147.90 ± 5.30

136.7 ± 11.1*

133.4 ± 4.94

152.80 ± 3.43

149.60 ± 3.66

151.70 ± 6.22

135.30 ± 7.11

144.40 ± 2.67

EC50 (μM)

0.26 (0.28–0.23)

15.7 (9.32–26.5)*

0.30 (0.20–0.44)

1.08 (0.71–6.70)*

11.9 (9.39–14.3)*

0.32 (0.30–0.34)***

0.31 (0.24–0.41)***

2.47 (1.59–3.83)**,***

10.6 (2.67–4.19)**

31.8

(17.1–43.6)**,***

fabp1b.1

 

WY14643

Rosiglitazone

 

-

GW6471

T0070907

Δ5’FR

ΔDR1

-

GW6471

T0070907

Δ5’FR

ΔDR1

E max (RLU)

152.30 ± 5.57

151.30 ± 4.91

148.7 ± 5.27

146.4 ± 3.52

152.80 ± 7.24

152.30 ± 5.67

148.30 ± 4.87

150.70 ± 7.96

147.80 ± 2.02

178.50 ± 8.68**

EC50 (μM)

0.29 (0.17–0.49)

1.08 (0.86–1.54)*

0.10 (0.07–0.19)

0.67 (0.48–0.95)

28.8 (17.3–48.1)*

0.11 (0.07–0.15)***

0.11 (0.08–0.15)***

2.40 (1.39–4.15)**,***

0.70 (0.56–0.89)**

54.5 (32.9–90.4)**

  1. Data derived from Figs. 4 and 5 presented as the mean ± SEM or 95 % confidence intervals (brackets)
  2. *P < 0.05 compared to WY14643 treatment alone within promoter
  3. **P < 0.05 compared to rosiglitazone treatment alone within promoter
  4. ***P < 0.05 rosiglitazone treatment compared to matched WY14643 treatment within promoter, as determined via two-way ANOVA followed by Bonferroni’s post-hoc analysis for E max, or by non-overlapping confidence intervals (EC50). n = 3
Back to article page

BMC Ecology and Evolution

ISSN: 2730-7182

Contact us